European Journal of Gastroenterology & Hepatology最新文献

{"title":"Hepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.","authors":"Nathalia I Crosewski, Aryadne H M Pereira, Luiz R Kotze, Maria Lúcia A Pedroso, Katia C Kampa, Leticia Rosevics, Thaisa K Furlan, Odery Ramos Junior","doi":"10.1097/MEG.0000000000003022","DOIUrl":"10.1097/MEG.0000000000003022","url":null,"abstract":"<p><p>Vedolizumab is a humanized antiintegrin α4β7 mAb, selective for the intestine, used in the treatment of moderate to severe inflammatory bowel disease. Safety studies show that vedolizumab has a 31% risk of serious adverse events, but reports of hepatotoxicity are rare. Previous case descriptions show that the lesion is mainly cholestatic or mixed, but hepatocellular lesion can also occur. We report a case of vedolizumab-associated hepatotoxicity in a patient with ulcerative colitis who had no previous liver disease. After starting treatment with vedolizumab, the patient presented elevated transaminases and canalicular in a cholestatic pattern, with normal liver imaging. Due to the suspicion of underlying hepatopathies such as primary sclerosing cholangitis and autoimmune hepatitis (AIH), a biopsy was performed, which showed a lymphocytic inflammatory infiltrate with lymphoid aggregates and eosinophils and plasma cells, as well as interface activity with 'spill-over' of lymphocytes to the parenchyma, which was interpreted as a lesion secondary to the drug. Discontinuation of vedolizumab led to a gradual improvement in liver tests. The case highlights the importance of monitoring liver tests in patients being treated with vedolizumab and the need to differentiate drug hepatotoxicity from other liver diseases.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"982-984"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive prediction model for predicting spontaneous tumor necrosis in hepatocellular carcinoma and prognostic study.","authors":"Qingyong Hong, Chunmin Li, Ziqiang Li, Zhidong Guo, Nadeem Ashraf, Kun Li","doi":"10.1097/MEG.0000000000002967","DOIUrl":"10.1097/MEG.0000000000002967","url":null,"abstract":"<p><strong>Background and objectives: </strong>In hepatocellular carcinoma (HCC), patients with spontaneous tumor necrosis have a high recurrence rate and poor prognosis. However, conventional preoperative imaging could not detect the presence of tumor necrosis. Accordingly, we developed and assessed a nomogram to forecast tumor necrosis.</p><p><strong>Methods: </strong>Clinical data were collected retrospectively from 495 patients with HCC who received a hepatectomy at Zhongnan Hospital of Wuhan University from 1 January 2015 to 31 May 2024. The patients ( n  = 495) were randomly divided in a 7 : 3 ratio into the training cohort (TC, n  = 348) and the validation cohort (VC, n  = 147). The logistic regression analyses were used to identify factors independently predicting tumor necrosis in the patients with TC. The Kaplan-Meier survival analysis was used for comparing and estimating survival rates.</p><p><strong>Results: </strong>Preoperative clinical tumor-node-metastasis stage, hemoglobin, systemic immune inflammation, alkaline phosphatase, and alpha-fetoprotein levels were identified as hazard factors for predicting tumor necrosis. The area under the receiver operating characteristic curve of the TC, VC, and the full cohort was 0.810, 0.758, and 0.795, respectively. The calibration curves demonstrated a high degree of concordance. The decision curve analysis showed the clinical significance of the nomogram. Both overall survival and recurrence-free survival of patients in the tumor necrosis group were poorer.</p><p><strong>Conclusion: </strong>Our predictive model could effectively predict the risk of spontaneous tumor necrosis in patients with HCC, and tumor necrosis was related to a worse prognosis.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"943-954"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram model for identifying portal vein thrombosis in patients with decompensated cirrhosis.","authors":"Wenting Lu, Yang Cheng, Rui Fang, Chuanfu Ding, Qin Yin, Ming Zhang, Jiangqiang Xiao, Bing Xu, Taishun Li, Lei Wang, Feng Zhang, Yuzheng Zhuge","doi":"10.1097/MEG.0000000000002968","DOIUrl":"10.1097/MEG.0000000000002968","url":null,"abstract":"<p><strong>Background and aims: </strong>Von Willebrand factor (vWF) plays a key role in hemostasis and is reported to be related to the outcome of advanced chronic liver disease. The present study aimed to investigate the relationship between vWF and other potential variables and portal vein thrombosis (PVT) in patients with decompensated cirrhosis.</p><p><strong>Methods: </strong>Consecutive cirrhotic patients with gastroesophageal varices were admitted to our hospital between January 2020 and September 2022. Patients were prospectively recruited and divided into PVT and non-PVT groups. We collected clinical tests, biochemical tests, coagulation tests, and hemostatic protein profile data to explore the associated factors of PVT.</p><p><strong>Results: </strong>A total of 128 patients were enrolled including 60 patients with PVT and 68 patients without PVT. Plasma levels of vWF [odds ratio (OR) = 1.015, 95% confidence interval (CI): 1.005-1.025, P  = 0.005], D-dimer (OR = 1.967, 95% CI: 1.141-3.389, P  = 0.015), and decreased portal vein velocity (PVV) (OR = 0.852, 95% CI: 0.769-0.944, P  = 0.002) were the variables independently associated with the existence of PVT. Area under the curve (AUC) analyses for vWF, D-dimer, and PVV were 0.779, 0.848, and 0.832, respectively. A nomogram model was established involving the three parameters, and the AUC was 0.919 (95% CI: 0.869-0.969). In the internal validation using bootstrap, the AUC was 0.919 (95% CI: 0.868-0.970).</p><p><strong>Conclusion: </strong>Higher vWF levels were related to PVT in patients with decompensated cirrhosis, indicating that vWF might serve as a relevant factor for PVT, and a nomogram containing vWF, D-dimer, and PVV could be an important tool for PVT identification in cirrhotic patients.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"935-942"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.","authors":"Michael Colwill, Samantha Baillie, Chandni Radia, Sarah White, Richard Pollok, Andrew Poullis","doi":"10.1097/MEG.0000000000002995","DOIUrl":"10.1097/MEG.0000000000002995","url":null,"abstract":"<p><strong>Objectives: </strong>Prompt initiation of advanced therapy medications, encompassing biologics and small-molecule treatments, is crucial for the effective management of inflammatory bowel disease (IBD). The time taken from the decision to start an advanced therapy to the first administration, or time to advanced therapy (TAT), can vary significantly between individuals and negatively affect disease course; however, our knowledge of the causes of variation in TAT is poor. We aimed to investigate the impact of demographic factors on delays in TAT.</p><p><strong>Methods: </strong>A retrospective study, conducted at a tertiary IBD referral centre, analysed electronic patient records of 1298 patients with IBD, and collected data on the TAT for their index advanced therapy. The variables studied included disease type, treatment, age, sex, ethnicity, and socioeconomic status, using index of multiple deprivation. Multiple negative binomial regression was performed to assess the relative effects of these variables on TAT.</p><p><strong>Results: </strong>TAT was significantly longer in the non-White ethnicity group ( P  = 0.039). Patients of Black ethnicity had an incident rate ratio (IRR) of 1.46 [95% confidence interval (CI): 1.09-1.95], for mixed ethnicity IRR = 1.26 (95% CI: 0.77-2.05) and for Asian IRR = 1.17 (95% CI: 0.96-1.41) compared with White patients. Adalimumab was also associated with a longer TAT ( P  ≤ 0.001; IRR = 1.37; 95% CI: 0.95-1.96).</p><p><strong>Conclusion: </strong>Non-White ethnicity is associated with a longer TAT, as is treatment with adalimumab which may be because of outsourcing of medication supply. Further research on the causes and strategies to address this health disparity is required.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"911-916"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.","authors":"Anna Riva, Gabriele Arienti, Giovanna Zuin, Laura Spini, Roberto Panceri, Andrea Biondi, Renata Nacinovich, Andrea E Cavanna","doi":"10.1097/MEG.0000000000002999","DOIUrl":"10.1097/MEG.0000000000002999","url":null,"abstract":"<p><strong>Introduction: </strong>Little is known about thepsychological correlates of inflammatory bowel diseases (IBDs) in the pediatric population. We, therefore, conducted a case-control study systematically exploring psychopathological profiles and alexithymia in adolescents with IBDs.</p><p><strong>Methods: </strong>We recruited 52 patients with IBDs (of whom 43 in clinical remission) and 52 age- and gender-matched healthy controls. All participants completed a validated psychometric battery assessing psychological symptoms Symptom Checklist-90-Revised and alexithymia Toronto Alexithymia Scale-20.</p><p><strong>Results: </strong>Adolescents with IBDs reported significantly higher scores across all psychopathological domains compared to controls, with more pronounced differences in depression and obsessive-compulsive symptoms (both P  < 0.001). However, there were no significant differences in alexithymia scores between the two groups.</p><p><strong>Conclusion: </strong>These findings underscore the psychological distress experienced by adolescents with IBDs, emphasizing the importance of early identification and intervention to prevent the development of fully fledged psychiatric disorders. Further research is needed to better characterize the psychopathological profiles of different clinical phenotypes of IBDs and to explore possible correlations with the clinical course of these chronic conditions.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"917-921"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.","authors":"Joaquín Borrás-Blasco, Alejandro Valcuende-Rosique, Silvia Cornejo","doi":"10.1097/MEG.0000000000003019","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003019","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"37 8","pages":"985-986"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlating endoscopic findings with pathology to optimize biopsy strategies in gastritis: insights from a large cohort study.","authors":"Fadi Abu Baker, Rawi Hazzan, Oren Gal, Randa Natour, Dorin Nicola, Amir Farah, Amir Mari","doi":"10.1097/MEG.0000000000003060","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003060","url":null,"abstract":"<p><strong>Background: </strong>Despite advancements in endoscopic technology, the concordance between endoscopic findings and histopathological diagnoses in gastritis remains inconsistent. This study aimed to evaluate the correlation between endoscopic and histopathological findings, identify predictors of pathological outcomes, and assess the role of biopsies in routine clinical practice.</p><p><strong>Methods: </strong>A retrospective analysis of 4927 gastroscopies with biopsy over 6 years was performed. Demographics, endoscopic features, and histopathological findings were analyzed. Logistic regression identified predictors of Helicobacter pylori infection and precancerous conditions, with predictive accuracy assessed using receiver operating characteristic (ROC) analysis. Endoscopic patterns were categorized according to structured classification systems, with severity and anatomical distribution systematically documented.</p><p><strong>Results: </strong>Normal biopsies were found in 28.6%, H. pylori in 33.6%, and histologically confirmed precancerous conditions - including atrophy, intestinal metaplasia, and low-grade dysplasia - in 13.5% of cases. Nodular gastropathy [odds ratio (OR) = 1.54, P = 0.0006] and erosive raised gastropathy (OR = 1.31, P = 0.037) predicted H. pylori infection, while atrophic-appearing gastropathy (OR = 8.42, P < 0.001) and erosive raised gastropathy (OR = 2.47, P < 0.001) strongly predicted precancerous lesions. Erythematous gastropathy was inversely associated with H. pylori and precancerous conditions. Predictive accuracy was moderate for H. pylori [area under the ROC curve (AUC) = 0.60] and good for precancerous conditions (AUC = 0.74).</p><p><strong>Conclusion: </strong>While certain endoscopic features and patient demographics may assist in identifying individuals at higher risk of significant pathology, their predictive value remains modest. These findings may contribute to future efforts aimed at risk stratification; however, histological assessment remains essential, and prospective validation is warranted before altering current biopsy practices.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia.","authors":"Francesco Calabrese, Andrea Pasta, Giorgia Bodini, Manuele Furnari, Federica Grillo, Luca Mastracci, Edoardo V Savarino, Vincenzo Savarino, Patrizia Zentilin, Edoardo G Giannini, Elisa Marabotto","doi":"10.1097/MEG.0000000000002989","DOIUrl":"10.1097/MEG.0000000000002989","url":null,"abstract":"<p><strong>Introduction and aim: </strong>Autoimmune chronic atrophic gastritis (ACAG) is a chronic autoimmune disorder whose diagnostic complexity arises from diverse symptoms mimicking other gastrointestinal disorders, often leading to misdiagnosis. Despite diagnosis, patients are often treated with proton pump inhibitors (PPIs) before consulting a gastroenterologist, emphasizing the need for accurate identification and management of ACAG in primary care. This study aimed to explore factors influencing disease progression.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed demographic data, medical history, use of PPI, and clinical, endoscopic, and histological data of consecutive adult patients with a histological diagnosis of ACAG referred to our outpatient clinic between January 2017 and December 2022. Operative link on gastritis assessment (OLGA) and operative link for gastric intestinal metaplasia assessment (OLGIM) were recorded for each patient.</p><p><strong>Results: </strong>Seventy patients with a diagnosis of ACAG (female 74.3%, median age 63.9 years) made up the study cohort. Eighteen patients were asymptomatic (25.7%), while 13 (18.6%), and 10 (14.3%) patients reported epigastric pain and asthenia, respectively. Median age at diagnosis of ACAG was 60.7 years [interquartile range (IQR): 46.4-68.2]. OLGA and OLGIM scores III and IV were associated with higher age at diagnosis (OLGA: 69.2 years, IQR: 65.2-75.1 vs. 57.1 years, IQR: 44.4-67.1, P  = 0.005; OLGIM; 68.0 years, IQR: 56.1-73 vs. 58.5 years, IQR: 44.3-67.4, P  = 0.031). The use of full-dose PPI was more frequent in patients with higher OLGA and OLGIM scores (OLGA I-II vs. III-IV: n  = 11, 17.7% vs. n  = 4, 50.0%, P  = 0.036; OLGIM 0-II vs. III-IV: n  = 10, 16.7% vs. n  = 5, 50.0%, P  = 0.017).</p><p><strong>Conclusion: </strong>ACAG patients with severe atrophy and those with severe gastric intestinal metaplasia were most likely PPI users. Timely diagnosis and heightened awareness among nongastroenterologists regarding the inappropriate use of PPI in this context are crucial.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"905-910"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the incidence and risk factors for the development of acute-on-chronic liver failure in outpatients with cirrhosis.","authors":"Guilherme John Neto, Gustavo Z Sbrissa, Jordano Bandera, Angelo A Mattos, Ângelo Z Mattos","doi":"10.1097/MEG.0000000000002974","DOIUrl":"10.1097/MEG.0000000000002974","url":null,"abstract":"<p><strong>Objective: </strong>Acute decompensation of cirrhosis is associated with high mortality, and acute-on-chronic liver failure is at the extreme of its spectrum of severity. This study aimed to evaluate the incidence and risk factors for the development of acute-on-chronic liver failure in outpatients with cirrhosis.</p><p><strong>Methods: </strong>This is a retrospective cohort study of consecutive patients with cirrhosis attending an outpatient clinic at a referral hospital in southern Brazil. Clinical, laboratory, and imaging data at the first outpatient visit were collected. The primary outcome of interest was the development of acute-on-chronic liver failure.</p><p><strong>Results: </strong>Three hundred patients with cirrhosis were included in the study. During a median follow-up of 56.5 months, 41 developed acute-on-chronic liver failure. The incidence of acute-on-chronic liver failure was 3.9% at 12 months, 7.0% at 24 months, 8.8% at 36 months, and 12.7% at 60 months. The cumulative incidence of acute-on-chronic liver failure was 23.0% at 84 months. Multivariate Cox regression analysis showed that baseline hemoglobin (hazard ratio of 0.78, 95% confidence interval: 0.67-0.90) and Child-Pugh score (hazard ratio of 1.70, 95% confidence interval: 1.44-2.00) were independently associated with the development of acute-on-chronic liver failure.</p><p><strong>Conclusions: </strong>Nearly one-fourth of outpatients with cirrhosis developed acute-on-chronic liver failure during follow-up, which was independently associated with low hemoglobin levels and poor liver function according to the Child-Pugh score at baseline.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"970-974"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.","authors":"Jakub Szlak, Agnieszka Magdziak, Andrzej Mróz, Paulina Wieszczy-Szczepanik, Jaroslaw Reguła, Edyta Zagórowicz","doi":"10.1097/MEG.0000000000003001","DOIUrl":"10.1097/MEG.0000000000003001","url":null,"abstract":"<p><strong>Objectives: </strong>The role of cytomegalovirus (CMV) infection in the course of inflammatory bowel disease is still controversial. We aimed to prospectively evaluate the course of ulcerative colitis in patients with exacerbation, in whom CMV status was examined using immunohistochemistry of bowel biopsies.</p><p><strong>Methods: </strong>In a single centre, we followed-up consecutive patients admitted for moderate or severe ulcerative colitis flare between 2016 and 2019. Colectomies, repeated hospitalisations, major treatment modifications, and quality of life (QoL) were recorded. The relationship between categorical variables was examined with the χ2 statistical test or Fisher's exact test.</p><p><strong>Results: </strong>Of 84 patients, 16 (19%) were CMV-positive. A Mayo endoscopic score of 3 was more frequent in CMV-positive than CMV-negative patients (81.2 vs. 51.5%; P  = 0.048) as was corticosteroid treatment (81.2 vs. 54.4%; P  = 0.015). Median follow-up was 2.1 years (range: 0.3-3.6 years). Colectomy was performed in 20 (23.8%) patients, with similar rates in CMV-positive (25%) and CMV-negative patients (23.5%; P  = 1.0). Similarly, no differences were found in the frequency of hospitalisation and QoL. The percentage of patients who started biological treatment was higher in the CMV-negative than in the CMV-positive group (58.8 vs. 18.8%; P  = 0.005).</p><p><strong>Conclusion: </strong>CMV infection was present in 19% of consecutive patients hospitalised for ulcerative colitis flare. Corticosteroid treatment and severe endoscopic lesions were observed more often in patients CMV-positive. In the following 2.1 years, the colectomy rate did not differ between patients CMV-positive and CMV-negative. Routine screening for CMV in ulcerative colitis exacerbation is not advisable.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":"922-929"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}